What question did this study set out to answer?

The aim is to identify molecular markers of neuroprotection related to dopamine neuron apoptosis in Parkinson's disease (PD).

March 2, 2026

Molecular markers of endogenous neuroprotection in the brain of rats with experimental Parkinson's disease treated with various pharmacotherapy regimens.

Key Points

The aim is to identify molecular markers of neuroprotection related to dopamine neuron apoptosis in Parkinson's disease (PD).
Experimental model using rats with induced Parkinson's disease
Treatment with various pharmacotherapy regimens including amantadine
Evaluation of neuroprotection and apoptosis markers
Comparison of effects of melatonin, cerebrocurin, pronoran, and gliatilin
Identification of apoptosis as a key factor in dopamine neuron loss
Effective modulation of neuroprotective markers with combined therapy regimen
Melatonin and other drugs show promise in enhancing neuroprotection against dopamine neuron apoptosis

Abstract

Conclusions: We have experimentally demonstrated a new target of neuroprotection in PD conditions - apoptosis of dopamine-producing neurons and substantiated modulators of this process - drugs for combined therapy with amantadine (melatonin, cerebrocurin, pronoran, and gliatilin) as promising drugs for PD treatment.

Bookmark

Cite This Study

Tyshchenko et al. (Thu,) studied this question.

synapsesocial.com/papers/69a52e34f1e85e5c73bf1bd3 https://doi.org/https://doi.org/10.36740/wlek/214337

Bookmark